NKTR · Nektar Therapeutics

-

-

Please sign in to comment on NKTR

1 Comment

Admin
4 years, 11 months ago

Nektar Therapeutics is currently in a long term downtrend where the price is trading 9.7% below its 200 day moving average.

From a valuation standpoint, the stock is 98.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 23.8.

Nektar Therapeutics's total revenue sank by 30.7% to $23M since the same quarter in the previous year.

Its net income has dropped by 3.3% to $-117M since the same quarter in the previous year.

Finally, its free cash flow grew by 22.1% to $-100M since the same quarter in the previous year.

Based on the above factors, Nektar Therapeutics gets an overall score of 2/5.












© PyInvesting 2026

About    Blog    Influencers   Careers   Contact Us   Disclaimer   Privacy Policy